Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. ownership disclosure: Point72 reporting persons state beneficial ownership of 276,831 shares of Common Stock, representing 1.9% of the class as of March 31, 2026.
The amendment names Point72 Asset Management, Point72 Capital Advisors, Point72 Biotech Private Investments, Differentiated Ventures, 72 Investment Holdings, and Steven A. Cohen and describes shared voting and dispositive power for the listed shares.
KRRO files a prospectus supplement to update its resale prospectus registering up to 7,650,764 shares of common stock, consisting of 4,501,928 shares and 3,148,836 shares issuable upon exercise of pre-funded warrants. This supplement substitutes SILV Fund, Ltd. for Point72 Associates, LLC as a selling stockholder for 540,054 shares. The supplement makes no other changes and reiterates that these shares were issued in a private placement under a subscription agreement dated March 9, 2026. The Nasdaq closing price on May 12, 2026 was $11.22 per share.
Korro Bio, Inc. reported a net loss of $19.6 million for the quarter ended March 31, 2026, improving from a $23.4 million loss a year earlier, as research and development and general and administrative costs declined. Collaboration revenue from Novo Nordisk fell to zero after a 12‑month pause of that agreement. Cash, cash equivalents and marketable securities rose to $157.1 million, driven by a March 2026 private placement and at‑the‑market share sales. The company expects this liquidity to fund operations into the second half of 2028 while advancing its OPERA RNA‑editing platform and lead program KRRO‑121 toward first‑in‑human studies.
Korro Bio reported first quarter 2026 results and highlighted progress across its RNA editing pipeline. Cash, cash equivalents and marketable securities were $157.1 million as of March 31, 2026, up from $85.2 million at year-end, helped by an oversubscribed $85 million private placement that is expected to fund operations into the second half of 2028.
The company advanced lead candidate KRRO-121 toward a planned regulatory filing in the second half of 2026 and achieved greater than 90% in vivo RNA editing in its GalNAc-conjugated AATD program. R&D expenses fell to $12.9 million from $19.7 million, while net loss narrowed to $19.6 million from $23.4 million year over year.
Korro Bio, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026 at 8:30 a.m. Eastern time. Holders of common stock as of April 13, 2026, when 14,422,571 shares were outstanding, may participate and vote online after advance registration.
Stockholders will elect two Class I directors, Nessan Bermingham and Rachel Meyers, for terms ending in 2029, cast a non-binding advisory vote on executive compensation, and ratify Ernst & Young LLP as auditor for 2026. The proxy details board structure, governance practices, and 2025 executive pay, including salary, bonuses, equity awards and severance arrangements.
Korro Bio, Inc. Schedule 13G/A shows Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 1,538,296 shares of Common Stock, representing 10.7% of 14,422,571 shares outstanding as of March 11, 2026. The disclosed position reflects shared voting and shared dispositive power over those shares.
Lynx1 Master Fund LP, an entity associated with Lynx1 Capital Management LP and Weston Nichols, reported an indirect open-market purchase of 520 shares of Korro Bio, Inc. common stock at $10.60 per share. Following this transaction, the reporting structure shows 1,538,296 shares held indirectly. Lynx1 Capital Management LP and Mr. Nichols each disclaim beneficial ownership except to the extent of any pecuniary interest.
Korro Bio, Inc. reported an initial insider ownership filing showing that investment entities associated with Lynx1 Capital Management LP and Weston Nichols indirectly hold 1,537,776 shares of common stock. The shares are held by Lynx1 Master Fund LP, and both the investment manager and Mr. Nichols disclaim beneficial ownership except for any pecuniary interest.
Korro Bio Inc — The Vanguard Group filed an amendment to a Schedule 13G/A stating it beneficially owns 0 shares of Korro Bio common stock, representing 0% of the class. The filing explains that, on January 12, 2026, The Vanguard Group underwent an internal realignment and certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.